Joël Oger

11.0k total citations · 1 hit paper
110 papers, 5.4k citations indexed

About

Joël Oger is a scholar working on Pathology and Forensic Medicine, Immunology and Rheumatology. According to data from OpenAlex, Joël Oger has authored 110 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Pathology and Forensic Medicine, 30 papers in Immunology and 19 papers in Rheumatology. Recurrent topics in Joël Oger's work include Multiple Sclerosis Research Studies (57 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Polyomavirus and related diseases (13 papers). Joël Oger is often cited by papers focused on Multiple Sclerosis Research Studies (57 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Polyomavirus and related diseases (13 papers). Joël Oger collaborates with scholars based in Canada, United States and France. Joël Oger's co-authors include D. W. Paty, L. F. Kastrukoff, Helen Tremlett, S. A. Hashimoto, Barry G.W. Arnason, John P. Hooge, Jack P. Antel, Irene M. Vavasour, Alex L. MacKay and K. Eisen and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Joël Oger

108 papers receiving 5.1k citations

Hit Papers

MRI in the diagnosis of MS 1988 2026 2000 2013 1988 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MRI in the diagnosis of MS
    1988 504 citations D. W. Paty, Joël Oger et al. profile →

Peers

Joël Oger
S. Fredrikson Sweden
Domenico Caputo Italy
Paolo Gallo Italy
John Rose United States
Claudio Gasperini Italy
Allan G. Kermode Australia
Gabriele C. DeLuca United Kingdom
Elizabeth Fisher United States
Ruggero Capra Italy
D. W. Paty Canada
S. Fredrikson Sweden
Joël Oger
Citations per year, relative to Joël Oger Joël Oger (= 1×) peers S. Fredrikson

Countries citing papers authored by Joël Oger

Since Specialization
Citations

This map shows the geographic impact of Joël Oger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joël Oger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joël Oger more than expected).

Fields of papers citing papers by Joël Oger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joël Oger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joël Oger. The network helps show where Joël Oger may publish in the future.

Co-authorship network of co-authors of Joël Oger

This figure shows the co-authorship network connecting the top 25 collaborators of Joël Oger. A scholar is included among the top collaborators of Joël Oger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joël Oger. Joël Oger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Thomas, Afsaneh Shirani, Yinshan Zhao, et al.. (2015). Beta‐interferon exposure and onset of secondary progressive multiple sclerosis. European Journal of Neurology. 22(6). 990–1000. 25 indexed citations
2.
Lawton, Michael, Kate Tilling, Neil Robertson, et al.. (2015). A longitudinal model for disease progression was developed and applied to multiple sclerosis. Journal of Clinical Epidemiology. 68(11). 1355–1365. 15 indexed citations
3.
4.
Shirani, Afsaneh, Yinshan Zhao, Mohammad Ehsanul Karim, et al.. (2012). Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA. 308(3). 247–56. 188 indexed citations
5.
Grossberg, Sidney E., et al.. (2011). Frequency and Magnitude of Interferon β Neutralizing Antibodies in the Evaluation of Interferon β Immunogenicity in Patients with Multiple Sclerosis. Journal of Interferon & Cytokine Research. 31(3). 337–344. 28 indexed citations
6.
Leray, Emmanuelle, Jacqueline Yaouanq, Emmanuelle Le Page, et al.. (2010). Evidence for a two-stage disability progression in multiple sclerosis. Brain. 133(7). 1900–1913. 406 indexed citations
7.
Farrell, Rachel, Tariq Aziz, Ebrima Gibbs, et al.. (2008). Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNβ in multiple sclerosis patients. Journal of Immunological Methods. 336(2). 113–118. 37 indexed citations
8.
Oger, Joël. (2007). Immunosuppression: Promises and failures. Journal of the Neurological Sciences. 259(1-2). 74–78. 13 indexed citations
9.
Boz, Cavit, Joël Oger, Ebrima Gibbs, & Sidney E. Grossberg. (2007). Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Multiple Sclerosis Journal. 13(9). 1127–1137. 34 indexed citations
10.
Oger, Joël. (2007). HTLV-1 infection and the viral etiology of multiple sclerosis. Journal of the Neurological Sciences. 262(1-2). 100–104. 15 indexed citations
11.
Castro‐Costa, Carlos Maurício de, Abelardo Araújo, Osvaldo Massaiti Takayanagui, et al.. (2006). Proposal for Diagnostic Criteria of Tropical Spastic Paraparesis/HTLV-I-Associated Myelopathy (TSP/HAM). AIDS Research and Human Retroviruses. 22(10). 931–935. 197 indexed citations
12.
Massart, Catherine, J Gibassier, Joël Oger, Emmanuelle Le Page, & Gilles Edan. (2006). Neutralizing antibodies to interferon beta in multiple sclerosis: Analytical evaluation for validation of a cytopathic effect assay. Clinica Chimica Acta. 377(1-2). 185–191. 9 indexed citations
13.
Laule, Cornelia, Irene M. Vavasour, George R. Moore, et al.. (2004). Water content and myelin water fraction in multiple sclerosis. Journal of Neurology. 251(3). 284–293. 306 indexed citations
14.
Coulthart, Michael B., et al.. (2000). HTLV Type I/II in British Columbia Amerindians: A Seroprevalence Study and Sequence Characterization of an HTLV Type IIa Isolate. AIDS Research and Human Retroviruses. 16(9). 883–892. 15 indexed citations
15.
Agius, Mark, Christine A. Kirvan, Anne L. Schafer, et al.. (1998). Rapsyn Antibodies in Myasthenia Gravisa. Annals of the New York Academy of Sciences. 841(1). 516–521. 30 indexed citations
16.
Clark, C. M., et al.. (1992). Sleep Disturbance, Depression, and Lesion Site in Patients With Multiple Sclerosis. Archives of Neurology. 49(6). 641–643. 94 indexed citations
17.
Oger, Joël, et al.. (1990). Interaction of Rubella Virus with Human Immune Cells I. Permissiveness of Lymphocyte Subpopulations. Viral Immunology. 3(2). 119–125. 2 indexed citations
18.
Koopmans, R. A., Joël Oger, L. F. Kastrukoff, et al.. (1989). Chronic progressive multiple sclerosis: Serial magnetic resonance brain imaging over six months. Annals of Neurology. 26(2). 248–256. 66 indexed citations
19.
Grosbois, B., Y Pawlotsky, Joël Oger, et al.. (1979). [Intrasynovial secretion of antibrucella antibodies].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 8(45). 3752–3752.
20.
Oger, Joël, et al.. (1976). [Major histocompatibility system in multiple sclerosis].. PubMed. 132(2). 89–97. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Fredrikson Breakdown of academic impact, for papers by Domenico Caputo Breakdown of academic impact, for papers by Paolo Gallo Breakdown of academic impact, for papers by John Rose Breakdown of academic impact, for papers by Claudio Gasperini Breakdown of academic impact, for papers by Allan G. Kermode Breakdown of academic impact, for papers by Gabriele C. DeLuca Breakdown of academic impact, for papers by Elizabeth Fisher Breakdown of academic impact, for papers by Ruggero Capra Breakdown of academic impact, for papers by D. W. Paty
Rankless by CCL
2026